Advertisement

Suppressor Cell Induction and Reticuloendothelial Cell Activation Produced in the Mouse by β 1–3 Glucan

  • F. J. Lejeune
  • A. Vercammen-Grandjean
  • P. Mendes da Costa
  • D. Bron
  • V. Defleur
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 121B)

Abstract

The insoluble polysaccharide β 1–3 glucan was shown to be the active component of zymosan for producing hyperplasia and hyperfunction of the reticuloendothelial (RE) system (9). Moreover, it was found to increase the protection against tumor grafts, bacterial and parasitic infections (2,3,7). Most of previous studies on the mechanisms whereby glucan seems to be an immunostimulant were performed after two or several injections of glucan (1,2,3). In order to evaluate the sequence of qualitative changes in RE system, and their reversibility, we used a single injection of glucan. The intravenous (i.v.) and intraperitoneal (i.p.) routes were compared in the study of functional changes of T and B lymphocytes and of mononuclear phagocytes.

Keywords

Acid Phosphatase Spleen Cell Peritoneal Macrophage Mononuclear Phagocyte Peritoneal Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burgaleta, C. and Golde, D. W., Cancer Res. 37 (1977) 1739.PubMedGoogle Scholar
  2. 2.
    Cook, J. A., Taylor, D., Cohen, C., Rodrigue, J., Malshet, V. and Di Luzio, N. R., In: Immune Modulation and Control of Neoplasia by Adjuvant Therapy, (Ed. M. A. Chirigos ), Raven Press, New York, (1978) 183.Google Scholar
  3. 3.
    Di Luzio, N. R., Hoffmann, E. O., Cook, J. A., Browder, W. and Mansell, P., Nat. Cancer Inst. Monogr.(1978) in press.Google Scholar
  4. 4.
    Graham, R. C., Jr. and Karnowsky, M. J., J. Histochem. Cytochem. 14 (1966) 291.PubMedCrossRefGoogle Scholar
  5. 5.
    LeJeune, F. J., Beaumont, E., Garcia, Y. and Regnier, R., Biomedicine 28 (1978) 48.PubMedGoogle Scholar
  6. 6.
    LeJeune, F. J. and Evans, R., Europ. J. Cancer 8 (1972) 54.Google Scholar
  7. 7.
    LeJeune, F. J., Song, M., Delville, J., Stadtsbaeder, S., Gillet, J. and Jacques, P. J., Europ. J. Cancer (1978) in press.Google Scholar
  8. 8.
    Mendes da Costa, P., Defleur, V., Vercammen-Grandjean, A. and LeJeune, F. J., Europ. J. Cancer (1978) in press.Google Scholar
  9. 9.
    Riggi, S. J., and Di Luzio, N. R., Amer. J. Physiol., 200 (1961) 297.PubMedGoogle Scholar
  10. 10.
    Scott, M. T., Cell. Immunol. 5 (1972) 459.PubMedCrossRefGoogle Scholar
  11. 11.
    Vercammen-Grandjean, A. F., and LeJeune, F. J., Production and mode of action of macrophage secretions that interfere with the in vitro incorporation of radioactive DNA precursors by tumour cells. In: The Macrophage and Cancer. - Proc. EURES Symposium Edimburg 1977 (Eds. K. James, B. McBride, A. Stuart ), (1977) 50.Google Scholar

Copyright information

© Plenum Press, New York 1980

Authors and Affiliations

  • F. J. Lejeune
    • 1
  • A. Vercammen-Grandjean
    • 1
  • P. Mendes da Costa
    • 1
  • D. Bron
    • 1
  • V. Defleur
    • 1
  1. 1.Laboratory of Oncology and Experimental Surgery Department of SurgeryInstitut Jules Bordet Centre des Tumeurs de l’Université Libre de BruxellesBruxellesBelgium

Personalised recommendations